Clerkenwell Health, a psychedelic-specialist clinical research firm, recently partnered with MYndspan, which will give medical researchers access to magnetoencephalography (MEG) scanners. MYndspan is a brain analytics firm that allows users to evaluate and monitor brain health to extend the healthy lifespan of the mind. This may be the first time MEG brain scanning technology has been availed for use in commercial clinical trials at Clerkenwell Health’s facility in central London.
Clerkenwell Health has been carrying out clinical trials on psychedelics since last autumn to support the development of pharmaceuticals.
Psychedelics are known to alter neural networks in the human brain, and with this technology, researchers can accurately monitor a participant’s brain function and activity, both prior to and after psychedelics have been administered. This will help the researchers better understand this mechanism of action while also offering insights into how psychedelic therapies affect the brain.
This new collaboration will also afford Clerkenwell’s clients with new data to better understand how the drugs they are developing work as well as their effectiveness. This will also help further the understanding of the role psychedelics play in helping manage various mental health and neurological conditions such as post-traumatic stress disorder and depression for the pharmaceutical companies conducting trials at Clerkenwell’s facility.
This partnership strengthens the cutting-edge status of Clerkenwell’s commercial facility in London and also positions the capital at the core of the budding medical psychedelics sector in Europe.
MYndspan COO and cofounder Caitlin Baltzer stated that this accurate and rapid scanning technology demystifies the brain and enables, through the data generated, researchers to gain an understanding of how treatments such as psychedelics affected underlying neural circuitry in the brain as well as brain activity, which is crucial to understanding and treating mental health conditions.
Clerkenwell Health CEO Tom McDonald added that the researchers were on a mission to transform the treatment of mental health conditions, noting that the partnership also offered its clients a facility to test the effectiveness of their drugs alongside top-notch technology that enables real-time evaluation of how these drugs in conjunction with therapy can treat these conditions that plague millions globally.
The news of this collaboration comes after the psychedelic clinical trials received the go-ahead by the MHRA.
In addition to this partnership, Clerkenwell is party to agreements with U.S. and Canadian-based drug developers such as PharmAla Biotech and Mindset Pharma. These agreements entail testing therapies for the treatment of different mental health conditions, including major depressive disorders, nicotine addiction and social anxiety in individuals with autism spectrum disorder.
This new collaboration expands the possibilities for the flurry of research activity that various companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) are undertaking in their quest to help humanity combat the different mental health illnesses that aren’t responding so well to the existing conventional treatments.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
